TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation

Oncogene

Volumn 26, Issue 35, 2007, Pages 5154-5162

  Pollice, A ^a   Sepe, M ^a   Villella, V R ^a   Tolino, F ^a   Vivo, M ^a   Calabro V ^a   La Mantia, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

N terminal ubiquitination; p14ARF; Proteasome; TBP 1

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BINDING PROTEIN; CYCLOHEXIMIDE; PROTEASOME; PROTEIN P14ARF; TAT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

AMINO ACID SEQUENCE; CELLS, CULTURED; HUMANS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEIN P14ARF; UBIQUITIN;

EID: 34547622820     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210313     Document Type: Article

References (27)

1. Bertwistle D, Sugimoto M, Sherr CJ. (2004). Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 24: 985-996.
2. Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, Kriwacki RK. (2001). Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 314: 263-277.
3. Chen Y, Sharp ZD, Lee WH. (1997). HEC binds to the seventh regulatory subunit of the 26 S proteasome and modulates the proteolysis of mitotic cyclins. J Biol Chem 272: 24081-24087.
4. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R et al. (2005). Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 25: 8874-8886.
5. Colucci-D'Amato GL, D'Alessio A, Califano D, Calì G, Rizzo C, Nitsch L et al. (2000). Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. J Biol Chem 275: 19306-19314.
6. Corn PG, McDonald III R, Herman JG, El-Deiry WS. (2003). Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 35: 229-237.
7. Gallagher SJ, Kefford RF, Rizos H. (2006). The ARF tumor suppressor. Int J Biochem Cell Biol 38: 1637-1641.
8. Gonzalez F, Delahodde A, Kodadek T, Johnston SA. (2002). Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis. Science 296: 548-550.
9. Itahana K, Bhat KP, Jin A, Ithana Y, Hawke D, Kobayashi R et al. (2003). Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 12: 1151-1164.
10. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019-2027.
11. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW et al. (2005). Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25: 1258-1271.
12. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. (2004). N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes and Dev 18: 1862-1874.
13. Lam YA, Lawson TG, Velayutham M, Zweier JL, Pickart CM. (2002). A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 416: 763-767.
14. Liu CW, Corboy MJ, DeMartino GN, Thomas PJ. (2003). Endoproteolytic activity of the proteasome. Science 299: 408-411.
15. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. (2000). Identification of a cryptic nucleolar-localization signal in MDM2. Curr Biol 10: 539-540.
16. Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N, Grossman SR. (2006). Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 26: 2360-2372.
17. Park BW, O'Rourke DM, Wang Q, Davis JG, Post A, Qian X et al. (1999). Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases. Proc Natl Acad Sci USA 96: 6434-6438.
18. Pollice A, Nasti V, Ronca R, Vivo M, Lo Iacono M, Calogero R et al. (2004). Functional and physical interaction of the human ARF tumor suppressor with Tat-binding Protein-1. J Biol Chem 279: 6345-6353.
19. Reef S, Zalckvar E, Shifman O, Bialik S, Sabanay H, Oren M et al. (2006). A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell 22: 463-475.
20. Rodway H, Llanos S, Rowe J, Peters G. (2004). Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 23: 6186-6192.
21. Russell SJ, Reed SH, Huang W, Friedberg EC, Johnston SA. (1999). The 19S regulatory complex of the proteasome functions independently of proteolysis in nucleotide excision repair. Mol Cell 3: 687-695.
22. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R et al. (2005). MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699-708.
23. Sharpless NE. (2004). Ink4a/Arf links senescence and aging. Exp Gerontol 39: 1751-1759.
24. Sharpless NE. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576: 22-38.
25. Sherr CJ. (2001). The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737.
26. Voges D, Zwickl P, Baumeister W. (1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068.
27. Weber JD, Kuo ML, Weber JD, Kuo ML, Bothner B, DiGiammarino EL et al. (2000). Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol and Cell Biol 20: 2517-2528.